<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jones MB</submitter><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NIGMS NIH HHS</funding><funding>NIH HHS</funding><pagination>7207-12</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4932940</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>113(26)</volume><pubmed_abstract>IgG carrying terminal ?2,6-linked sialic acids added to conserved N-glycans within the Fc domain by the sialyltransferase ST6Gal1 accounts for the anti-inflammatory effects of large-dose i.v. Ig (IVIg) in autoimmunity. Here, B-cell-specific ablation of ST6Gal1 in mice revealed that IgG sialylation can occur in the extracellular environment of the bloodstream independently of the B-cell secretory pathway. We also discovered that secreted ST6Gal1 is produced by cells lining central veins in the liver and that IgG sialylation is powered by serum-localized nucleotide sugar donor CMP-sialic acid that is at least partially derived from degranulating platelets. Thus, antibody-secreting cells do not exclusively control the sialylation-dependent anti-inflammatory function of IgG. Rather, IgG sialylation can be regulated by the liver and platelets through the corresponding release of enzyme and sugar donor into the cardiovascular circulation.</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>B-cell-independent sialylation of IgG.</pubmed_title><pmcid>PMC4932940</pmcid><funding_grant_id>R01 HL056652</funding_grant_id><funding_grant_id>R24 GM098791</funding_grant_id><funding_grant_id>U54 GM062116</funding_grant_id><funding_grant_id>DP2 OD004225</funding_grant_id><funding_grant_id>T32 AI007024</funding_grant_id><funding_grant_id>R01 GM082916</funding_grant_id><funding_grant_id>F32 AI114109</funding_grant_id><funding_grant_id>T32 AI089474</funding_grant_id><pubmed_authors>Oswald DM</pubmed_authors><pubmed_authors>Orlando R</pubmed_authors><pubmed_authors>Jones MB</pubmed_authors><pubmed_authors>Joshi S</pubmed_authors><pubmed_authors>Cobb BA</pubmed_authors><pubmed_authors>Whiteheart SW</pubmed_authors></additional><is_claimable>false</is_claimable><name>B-cell-independent sialylation of IgG.</name><description>IgG carrying terminal ?2,6-linked sialic acids added to conserved N-glycans within the Fc domain by the sialyltransferase ST6Gal1 accounts for the anti-inflammatory effects of large-dose i.v. Ig (IVIg) in autoimmunity. Here, B-cell-specific ablation of ST6Gal1 in mice revealed that IgG sialylation can occur in the extracellular environment of the bloodstream independently of the B-cell secretory pathway. We also discovered that secreted ST6Gal1 is produced by cells lining central veins in the liver and that IgG sialylation is powered by serum-localized nucleotide sugar donor CMP-sialic acid that is at least partially derived from degranulating platelets. Thus, antibody-secreting cells do not exclusively control the sialylation-dependent anti-inflammatory function of IgG. Rather, IgG sialylation can be regulated by the liver and platelets through the corresponding release of enzyme and sugar donor into the cardiovascular circulation.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jun</publication><modification>2020-10-09T07:31:23Z</modification><creation>2019-03-27T02:17:35Z</creation></dates><accession>S-EPMC4932940</accession><cross_references><pubmed>27303031</pubmed><doi>10.1073/pnas.1523968113</doi></cross_references></HashMap>